타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr) BeOne Medicines·PD-1 213 trials·t½ ~20 days class range |
|---|---|
Overview Program | Tevimbra (tislelizumab) |
Overview Company | BeOne Medicines |
Overview Modality | ANTIBODY |
Overview Target | PD-1 |
Overview Indication | Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and chemotherapy |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Not a Keytruda substitute. The 2026 GEA label is a HER2-selected triplet with zanidatamab, not a PD-L1-unselected 1L PD-1 row. |
Positioning Known limitation | Antigen-presentation loss, alternate checkpoints, immunosuppressive TME. |
Positioning Development positioning | 1L–2L gastroesophageal, regimen-dependent |
MoA Mechanism | Binds PD-1 on T cells, blocking PD-L1/PD-L2 engagement and restoring antitumor T-cell activity. Fc silencing is intended to avoid macrophage-mediated T-cell clearance. |
MoA Biomarker | PD-L1 and tumor type on older labels; HER2 IHC/ISH when given with Ziihera. |
PK/PD Half-life | ~20 days class range |
PK/PD Species | OS/PFS, radiographic response |
PK/PD Animal (cat.) | Human |
Toxicology Major finding | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. |
Toxicology CRS | N/A |
Clinical Safety signal | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. |
Clinical Program phase | APPROVED |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr) BeOne Medicines·PD-1 213 trials·t½ ~20 days class range |
|---|---|
Overview Program | Tevimbra (tislelizumab) |
Overview Company | BeOne Medicines |
Overview Modality | ANTIBODY |
Overview Target | PD-1 |
Overview Indication | Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and chemotherapy |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Not a Keytruda substitute. The 2026 GEA label is a HER2-selected triplet with zanidatamab, not a PD-L1-unselected 1L PD-1 row. |
Positioning Known limitation | Antigen-presentation loss, alternate checkpoints, immunosuppressive TME. |
Positioning Development positioning | 1L–2L gastroesophageal, regimen-dependent |
MoA Mechanism | Binds PD-1 on T cells, blocking PD-L1/PD-L2 engagement and restoring antitumor T-cell activity. Fc silencing is intended to avoid macrophage-mediated T-cell clearance. |
MoA Biomarker | PD-L1 and tumor type on older labels; HER2 IHC/ISH when given with Ziihera. |
PK/PD Half-life | ~20 days class range |
PK/PD Species | OS/PFS, radiographic response |
PK/PD Animal (cat.) | Human |
Toxicology Major finding | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. |
Toxicology CRS | N/A |
Clinical Safety signal | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. |
Clinical Program phase | APPROVED |
추천 비교
추천 비교